Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 652 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Mother Of 6 With ‘Open-Door Policy’ Packs 100 Lunches For Hungry... September 18, 2019 Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among... August 25, 2025 Becoming My Own Advocate While Living With a Rare Cancer: A... April 27, 2023 SARS-CoV-2 Antibodies Can Protect from Reinfection, NCI Study Suggests December 21, 2020 Load more HOT NEWS The rise of the ‘long-waiter’ – why cancer waiting times are... Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,... ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and...
